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Abstract 
Background: A phase II clinical trial of the comparison between eribulin plus gemcitabine (EG) and paclitaxel plus 
gemcitabine (PG) as first‑line chemotherapy for patients with metastatic breast cancer (MBC) found that the EG regi‑
men was less neurotoxic, but was similar in efficacy to the PG regimen. In the present study, we analyzed functional 
assessment of cancer therapy‑taxane (FACT‑Taxane) questionnaires from patients in this clinical trial to determine their 
quality of life (QoL).
Methods: QoL was assessed using the Korean version of the FACT‑Taxane questionnaires. After baseline assessment, 
QoL was assessed every 2 cycles for 12 cycles and every 3 cycles thereafter. The linear mixed model was used to 
evaluate the difference in QoL between the EG and PG arms.
Results: Of the 118 enrolled patients, 117 responded to the FACT‑Taxane questionnaires at baseline, 1 in the PG 
arm did not. Baseline QoL scores were not different between the EG and PG arms. During treatment, taxane subscale 
scores were significantly higher in the PG arm than in the EG arm after 2–13 cycles of chemotherapy (all P < 0.05), 
except for the 11th cycle. Neuropathy‑specific analysis showed that patients in the PG arm had earlier and more 
severe neuropathic symptoms than those in the EG arm (P < 0.001).
Conclusions: In our QoL analysis, the EG regimen delayed and decreased neuropathy as compared with the PG regi‑
men. Therefore, eribulin would be a reasonable substitute for paclitaxel as first‑line chemotherapy for MBC.
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Background
The goal of palliative chemotherapy is to prolong survival 
without cancer-related symptoms. Therefore, patient-
reported quality of life (QoL), as like as survival outcome, is 
an important endpoint in evaluating treatment efficacy in 
metastatic breast cancer (MBC) patients [1]. Moreover, QoL 
of MBC patients was an independent prognostic marker [2].
Paclitaxel is an effective chemotherapeutic agent and 
an essential part of treatment for MBC patients [3, 4]. 
However, it leads to neuropathy in most patients, and 
severe neuropathy is a main reason for discontinuation 
of treatment. Previous studies of adjuvant taxane chem-
otherapy presented that about 20%–30% of patient had 
persistent peripheral neuropathy after chemotherapy 
discontinuation [5, 6]. In metastatic setting, paclitaxel 
plus gemcitabine (PG regimen) followed by mainte-
nance gemcitabine prolonged progression-free survival 
and overall survival, but approximately 90% of patients 
experienced grade 2–3 neuropathy [7]. Moreover, chem-
otherapy-induced peripheral neuropathy had a negative 
association with QoL of patients [8]. Therefore, preven-
tion of neuropathy may improve QoL of patients with 
breast cancer during treatment.
Eribulin, a non-taxane microtubule inhibitor, is an 
effective therapeutic agent for MBC patients [9]. It 
induced neuropathy in about 30% of patients, which was 
significantly lower than the rate of paclitaxel-induced 
neuropathy [10]. Taking this into account, we conducted 
a phase II, multicenter, randomized, open-labeled clinical 
trial comparing eribulin plus gemcitabine (EG regimen) 
with PG regimen as first-line chemotherapy for patients 
with human epidermal growth factor receptor 2 (HER2)-
negative MBC (the Korean Cancer Study Group [KCSG] 
BR13-11, Clinicaltrials.gov, NCT02263495) [11]. This 
clinical trial determined that treatment with EG resulted 
in similar outcomes as treatment with PG, but was less 
neurotoxic. Other toxicities of both treatments were 
reported at comparable levels.
In the present study, we analyzed QoL of participating 
patients in this clinical trial using the functional assess-
ment of cancer therapy-taxane (FACT-Taxane) question-
naires. Especially, we focused on chemotherapy-induced 
peripheral neuropathy in the two therapeutic arms.
Patients and methods
Patient selection
Women with histologically confirmed HER2-negative 
MBC and with no history of chemotherapy for meta-
static disease were eligible for KCSG BR13-11 trial [11]. 
Patients were eligible for the study if at least 12 months 
had passed since the completion of prior chemotherapy, 
even if they had received an anthracycline- or taxane-
containing regimen as neoadjuvant or adjuvant therapy. 
Patients with grade 2 or higher peripheral neuropathy 
were excluded.
Chemotherapy
Patients were randomly assigned, in a 1:1 ratio, to either 
the EG or PG treatment arm using interactive web 
response system (IWRS) [11]. EG chemotherapy com-
prised intravenous administration of 1.0 mg/m2 eribulin 
and 30-min intravenous infusion of 1000 mg/m2 gemcit-
abine on days 1 and 8 every 3 weeks. PG chemotherapy 
comprised intravenous administration of 175  mg/m2 
paclitaxel on day 1 with 30-min intravenous infusion of 
1250 mg/m2 gemcitabine on days 1 and 8 every 3 weeks.
The KCSG BR13-11 trial was conducted in full accord-
ance with the guidelines for Good Clinical Practice and 
the Declaration of Helsinki, and was approved by the 
institutional ethics committees of each hospital and the 
KCSG institutional review board. The ClinicalTrials.gov 
identifier number was NCT02263495. Written informed 
consent for publication of their clinical details was 
obtained from all patients.
Neurotoxicity was assessed at the end of each cycle 
using National Cancer Institute Common Toxicity Crite-
ria (NCI-CTC), version 4.0.
QoL assessment
QoL was assessed using the Korean version of the FACT-
Taxane questionnaires, which comprise the FACT-gen-
eral (FACT-G) and taxane subscale questionnaires [12]. 
FACT-G contains four subscales measuring physical 
well-being (PWB), social well-being (SWB), emotional 
well-being (EWB), and functional well-being (FWB). The 
four subscales contain 7, 7, 6, and 7 items, respectively. 
The taxane subscale is a 16-item self-reporting ques-
tionnaire that focuses on patient-reported neuropathic 
symptoms and concerns. The FACT questionnaires use a 
5-point response scale: 0 indicates not at all; 1, a little bit; 
2, somewhat; 3, quite a bit; and 4, very much. The ranges 
of scores are 0–108 for FACT-G and 0–64 for taxane sub-
scale. In FACT-G, the ranges of possible scores for the 
physical, social, emotional, and functional subscales are 
0–28, 0–28, 0–24, and 0–28, respectively.
Patients were asked to complete the first QoL assess-
ment before randomization. QoL was assessed every 
2 chemotherapy cycles for 12 cycles and every 3 cycles 
Keywords: Metastatic breast cancer, Eribulin, Paclitaxel, Neuropathy, Quality of life, Functional assessment of cancer 
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thereafter. Assessment continued until the treatment was 
terminated due to disease progression, withdrawal, and 
intolerable adverse events.
Statistical analyses
Differences in patient reports between the two treat-
ment arms were calculated using the Student t test. QoL 
scores (mean and standard deviation) were calculated 
at baseline and each assessed point for the overall scale 
(the sum of all subscales) as well as for the PWB, SWB, 
EWB, FWB, and taxane subscales. The linear mixed 
model was used to examine the QoL difference between 
the two treatment arms. The time to neuropathy onset 
was reported using the reverse Kaplan–Meier method. 
Relative dose intensity was defined as the amount of drug 
administered per unit time that expressed as a percentage 
of the planned dose or standard regimen. A two-sided P 
value < 0.05 was considered significant. SPSS Statistics 
ver. 21 (IBM Co., Armonk, NY, USA) was used for analy-
sis of all data.
Results
Patient characteristics
Between December 2014 and March 2016, a total of 118 
patients were enrolled and randomly assigned to either 
the EG arm or the PG arm at a ratio of 1:1. The median 
number of chemotherapy cycles was 10 (range 3–40) in 
the EG arm and 8 (range 2–34) in the PG arm. Of the 118 
patients, 1 in the PG arm did not respond to the FACT-
Taxane questionnaires at baseline, and 7 in the EG arm 
did not respond at the end of treatment. In terms of 
fidelity of questionnaire, no incomplete responses were 
recorded. Overall, the complete response rate was 99.0%. 
Additional file 1: Table S1 shows the number of patients 
enrolled in this study and the number of those who 
responded to questionnaires in each arm.
Changes in general QoL during treatment
We assessed treatment-related changes in FACT-G 
scores between the two arms. No differences in PWB, 
SWB, EWB, FWB, and overall scores at baseline and dur-
ing treatment were observed (all P > 0.05) (Fig. 1).
Changes in taxane‑associated QoL during treatment
The baseline taxane subscale score did not differ between 
the EG and PG arms (P = 0.684). During treatment, the 
taxane subscale score was found to increase earlier in 
the PG arm than in the EG arm. Overall, taxane subscale 
scores were higher in the PG arm than in the EG arm, 
but with no significant differences (P = 0.086) (Additional 
file 1: Table S2). During the first 13 cycles of treatment, 
the taxane subscale score was significantly higher in the 
PG arm than in the EG arm (all P < 0.05), except for the 
assessment at the 11th cycle; after then, no significant 
difference between the two arms was observed (Fig. 2a).
We performed subgroup analysis according to cycles 
of treatment. Because relative dose intensities of eribulin 
and paclitaxel were crossed at the 11th cycle of treatment 
(Additional file  2: Fig. S1), we chose the 13th cycle as 
cut-off value of treatment according to the point of QoL 
assessment and divided each arm into two subgroups: 
patients treated with less than 13 cycles and over 13 
cycles. Patients treated with less than 13 cycles of PG had 
the highest taxane subscale score among the four sub-
groups (P < 0.001) (Fig. 2b and Additional file 1: Table S3). 
Compared between the two subgroups of less than 13 
cycles, the mean taxane subscale score in the PG arm was 
almost twice as high as that in the EG arm (P < 0.001). 
However, the mean score did not differ between the two 
subgroups of over 13 cycles (P = 0.498) (Additional file 1: 
Table S3).
Of the 16 items of the taxane subscale, nine were 
neuropathy-specific questions. We further analyzed the 
intensity of chemotherapy-induced peripheral neuropa-
thy. The trend of changes in neuropathy-specific subset 
scores was similar to that of taxane subscale scores for 
both arms and for the four subgroups (Fig.  2c, d and 
Additional file 1: Table S3).
Peripheral neuropathy according to treatment
The cumulative rate of peripheral neuropathy was ana-
lyzed. Of the 118 patients, 89 experienced neuropathy: 54 
in the PG arm and 35 in the EG arm (Fig. 3a). Moreover, 
patients in the PG arm had earlier development after a 
median of 2 cycles as compared with those in the EG arm 
after a median of 6 cycles (P < 0.001).
Thirty-four patients had peripheral neuropathy of 
grade 2 or higher: 27 in the PG arm and seven in the 
EG arm (Fig.  3b). The median time to development of 
peripheral neuropathy of grade 2 or higher was after 8 
cycles in the PG arm and was not reached in the EG arm 
(P < 0.001).
Due to neuropathy, 16 (27.1%) patients in the PG arm 
and 3 (5.1%) in the EG arm required sequential dose 
modification. Fifteen of the 16 patients in the PG arm had 
dose reduction before completing 13 cycles of treatment, 
whereas the 3 EG patients in the EG arm did so at the 
9th, 19th, and 21st cycles. The PG treatment was discon-
tinued in 40 patients due to disease progression (55.0%), 
discretion of physician and patients (30.0%), adverse 
events (7.5%), and other reasons (7.5%) during the first 
13 cycles of treatment. Thirty-five patients stopped EG 
treatment because of disease progression (85.7%), dis-
cretion (5.7%), adverse events (5.7%), and other reasons 
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Fig. 1 Functional assessment of cancer therapy (FACT)‑General for the quality of life of patients with human epidermal growth factor receptor 2 
(HER2)‑negative metastatic breast cancer (MBC) in the eribulin plus gemcitabine (EG) and paclitaxel plus gemcitabine (PG) arms. a Overall scores; 
b physical well‑being (PWB) scores; c social well‑being (SWB) scores; d emotional well‑being (EWB) scores; e functional well‑being (FWB) scores. All 
data are presented as mean values, with bars indicate standard deviation
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(2.9%). Actually, the relative dose intensity of eribulin was 
slightly decreased, whereas that of paclitaxel decreased at 
every cycle of treatment (Additional file 2: Fig. S1).
Discussion
In our analysis of QoL, we found that EG chemotherapy 
delayed and decreased taxane-induced peripheral neu-
ropathy as compared with PG chemotherapy. Although 
no significant difference was observed between the two 
arms during entire duration of treatment, the subgroup 
of patients who received less than 13 cycles of PG treat-
ment had significantly more taxane-induced peripheral 
neuropathy than other subgroups.
These results were compatible with the data of physician-
reported peripheral neuropathy. The events of periph-
eral neuropathy increased rapidly in PG arm till 13th 
cycles and the difference between EG and PG arms were 
expanded. Neuropathy occurred in relatively early period 
of treatment, and some patients withdrew their treatment 
due to neuropathy. Patient without neuropathy continued 
their treatment, and therefore there were no significant 
differences in QoL scores between the EG and PG arms 
after the 13th cycle. In addition, some patients in the EG 
arm developed neuropathy during later cycles, but many 
patients reported low neuropathy-specific subset scores.
Patient-reported QoL outcomes reflect quality of pal-
liative care for cancer patients. QoL reporting was an 
independent prognostic marker, therefore many clinical 
trials for cancer patients analyzed patient-reported QoL 
data as a secondary endpoint [13]. Moreover, patient-
reporting outcome measures have been considered as 
a routine practice nowadays [14]. Although our QoL 
analysis showed that there was little difference between 
patient- and physician-reported neuropathy, the analysis 
of patient-reported QoL data is needed for the prediction 
of prognosis.
Fig. 2 Taxane subscale scores for patients with HER2‑negative MBC in the EG and PG arms. a Taxane subscale scores for the EG and PG arms; b 
taxane subscale scores for patients treated with less than 13 cycles or over 13 cycles of the EG or PG regimen; c neuropathy‑specific subset scores 
for the EG and PG arms; d neuropathy‑specific subset scores for patients treated with less than 13 cycles or over 13 cycles of the EG or PG regimen. 
All data are presented as mean values, with bars indicate standard deviation
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In the present study, we found no significant differences 
in PWB, EWB, SWB, FWB, and overall scores between 
the EG and PG arms. Similarly, previous studies showed 
that taxane-based chemotherapy did not affect QoL scores 
assessed using the FACT-G questionnaire and other QoL 
questionnaires without taxane-specific questions [15–17].
Paclitaxel-induced peripheral neuropathy is related 
to high cumulative dose and high dose per cycle [18, 
19]. In the present study, about 90% of patients treated 
with paclitaxel reported neuropathic symptoms. This 
is consistent with reported data from a previous PG 
maintenance study, which showed that nearly 90% of 
neuropathies occurred after 6 cycles of PG treatment 
[7]. In spite of the high rate of neuropathy, there are no 
definite preventive or treatment measures of neuropa-
thy [20]. The American Society of Clinical Oncology 
(ASCO) guidelines for prevention and management of 
chemotherapy-induced peripheral neuropathy indicate 
that there are no agents for neuropathy prevention [21]. 
Duroxetine is recommended, but neuropathic pain still 
existed in half of patients after duroxetine treatment [22]. 
Eribulin also induces peripheral neuropathy, but with 
lower rate and grade as compared with those induced 
by taxane. EMBRACE, a phase III clinical trial of eribu-
lin monotherapy, showed that 35% of eribulin-treated 
patients reported peripheral neuropathy, but only 8.2% 
were in grade 3–4 [10]. It was also reported that eribulin-
induced neuropathic pain was alleviated in most patients 
within a short period [23]. Therefore, for patients at risk 
for paclitaxel-induced neuropathy [24], eribulin might be 
a good substitute.
The limitation of the present study was that this phase 
II clinical trial had a relatively small sample size. To con-
firm our results, a large-scale phase III clinical trial of 
comparison between eribulin and paclitaxel would be 
warranted.
Conclusions
In the present QoL study, EG treatment decreased tax-
ane-related adverse events, especially neuropathy, as 
compared with PG treatment. Accordingly, eribulin 
would be a reasonable substitute for paclitaxel as first-
line chemotherapy for MBC.
Additional files
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Additional file 2: Figure S1. Relative dose intensities of eribulin and 
paclitaxel on each cycle. The red lines indicate trends of both arms.
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